No Data
US Stock MarketDetailed Quotes
PRPH ProPhase Labs
Watchlist
5.070
+0.400+8.57% Close 11/30 16:00 ET
5.0700.0000.00%
Pre 07:16 ET
5.700High4.875Low47.63KVolume
5.140Open4.670Pre Close250.19KTurnover0.34%Turnover RatioLossP/E (TTM)91.49MMarket Cap10.86052wk High4.97P/E (Static)18.05MShares4.05052wk Low1.62P/B71.32MFloat Cap15.250Historical High--Dividend TTM14.07MShs Float0.260Historical Low--Div YieldTTM17.67%Amplitude5.252Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About ProPhase Labs Company
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Diagnostic services108.33M88.33%
Consumer products14.32M11.67%
News
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Lowers Price Target to $11
HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and lowers the price target from $14 to $11.
ProPhase Labs Reports Q3 Results
ProPhase Labs Q3 EPS $(0.30) Misses $(0.20) Estimate, Sales $8.37M Miss $13.06M Estimate
ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.20) by 50 percent. This is a 600 percent decrease over earnings of $0.06 p
Comments
$ProPhase Labs(PRPH.US$ target 9.8
1
WATCHLIST 06/13 MONDAY
$Annovis Bio(ANVS.US$
- NIA and Annovis will collaborate to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived extracellular vesicles containing potential neuronal function and viability biomarkers. Stock got analyst price target of $37
$ProPhase Labs(PRPH.US$
- Last month the company announced better than expected earnings and announced a dividend. Received Analyst price target of $14.
$JE Cleantech Holdings Limited(JCSE.US$
- Stock rece...
- NIA and Annovis will collaborate to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived extracellular vesicles containing potential neuronal function and viability biomarkers. Stock got analyst price target of $37
$ProPhase Labs(PRPH.US$
- Last month the company announced better than expected earnings and announced a dividend. Received Analyst price target of $14.
$JE Cleantech Holdings Limited(JCSE.US$
- Stock rece...
3
1
WATCHLIST 06/09 THURSDAY
$Vertex Energy(VTNR.US$
- Vertex Energy Set To Join Russell 3000 Index June 27. Stock could continue higher pre joining.
$RCM Technologies(RCMT.US$
- Stock recently broke out. Currently consolidating above $25. Possible another break out soon.
$Tarena International(TEDU.US$
- On Tuesday , Co reported Q1 EPS $0.40 Up From $(0.31) YoY, Sales $98.36M Beat $58.85M Estimate. Stock breaking out.
$Annovis Bio(ANVS.US$
- NIA and Annovis will collaborate to develop pharmac...
- Vertex Energy Set To Join Russell 3000 Index June 27. Stock could continue higher pre joining.
$RCM Technologies(RCMT.US$
- Stock recently broke out. Currently consolidating above $25. Possible another break out soon.
$Tarena International(TEDU.US$
- On Tuesday , Co reported Q1 EPS $0.40 Up From $(0.31) YoY, Sales $98.36M Beat $58.85M Estimate. Stock breaking out.
$Annovis Bio(ANVS.US$
- NIA and Annovis will collaborate to develop pharmac...
2
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--